Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example.
暂无分享,去创建一个
Markus Schulz | Bernd Becker | Norbert Nagel | Bernhard Otto | M. Feth | M. Schulz | B. Baumgartner | B. Becker | Martin P Feth | Michael Spitzenberg | Bruno Baumgartner | Martin Bröckelmann | David Rigal | Franceska Fischer | Christine Petzoldt | M. Spitzenberg | N. Nagel | Christine Petzoldt | M. Bröckelmann | D. Rigal | B. Otto | F. Fischer
[1] Heribert Häusler,et al. Influence of mechanical activation on the physical stability of salbutamol sulphate. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[2] S. Reutzel,et al. Origins of the unusual hygroscopicity observed in LY297802 tartrate. , 1998, Journal of pharmaceutical sciences.
[3] H. Edwards,et al. Metamorphosis of caffeine hydrate and anhydrous caffeine , 1997 .
[4] M. Feth,et al. New technology for the investigation of water vapor sorption-induced crystallographic form transformations of chemical compounds: a water vapor sorption gravimetry-dispersive Raman spectroscopy coupling. , 2011, Journal of pharmaceutical sciences.
[5] P. Darcy,et al. Assessment of disorder in crystalline powders--a review of analytical techniques and their application. , 1999, International journal of pharmaceutics.
[6] L. Duclaux,et al. High-temperature furnace for INEL CPS 120 , 1997 .
[7] N. Urbanetz,et al. Quantifying the Degree of Disorder in Micronized Salbutamol Sulfate Using Moisture Sorption Analysis , 2007, Drug development and industrial pharmacy.
[8] Jung Min Park,et al. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry. , 2002, International journal of pharmaceutics.
[9] S. Balbach,et al. Pharmaceutical evaluation of early development candidates "the 100 mg-approach". , 2004, International journal of pharmaceutics.
[10] M. Feth,et al. Physicochemical, crystallographic, thermal, and spectroscopic behavior of crystalline and X-ray amorphous ciclesonide. , 2008, Journal of pharmaceutical sciences.
[11] P. Dell'orco,et al. A study of variable hydration states in topotecan hydrochloride. , 2006, Journal of pharmaceutical and biomedical analysis.
[12] P. Royall,et al. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. , 1999, International journal of pharmaceutics.
[13] N Midoux,et al. Micronization of pharmaceutical substances in a spiral jet mill , 1999 .
[14] H. Ehrenberg,et al. The synchrotron powder diffractometer at beamline B2 at HASYLAB/DESY: status and capabilities. , 2004, Journal of synchrotron radiation.
[15] Chandan Bhugra,et al. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. , 2008, Journal of pharmaceutical sciences.
[16] L. S. Taylor,et al. Manipulating hydrate formation during high shear wet granulation using polymeric excipients. , 2009, Journal of pharmaceutical sciences.
[17] Moisés Frías,et al. Determination of specific surface area by the laser diffraction technique. Comparison with the blaine permeability method , 1991 .
[18] M. Ticehurst,et al. Characterisation of the influence of micronisation on the crystallinity and physical stability of revatropate hydrobromide. , 2000, International journal of pharmaceutics.
[19] M. Kramer,et al. New high temperature furnace for structure refinement by powder diffraction in controlled atmospheres using synchrotron radiation , 1999 .
[20] J. Authelin. Thermodynamics of non-stoichiometric pharmaceutical hydrates. , 2005, International journal of pharmaceutics.
[21] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[22] Robert K. Schultz,et al. Process-Induced Crystallinity Changes in Albuterol Sulfate and Its Effect on Powder Physical Stability , 1995, Pharmaceutical Research.
[23] Ralph A. DeFronzo,et al. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.